Dr. Petros Karamanlakis, MD

Dr. Karamanlakis practices at Pk Medical in Pittsburgh, Pennsylvania.

Dr. Karamanlakis' NPI, 1629155908, was assigned on November 1, 2006. Dr. Karamanlakis holds New York license 241684.

Dr. Karamanlakis' primary practice is Pk Medical, at 820 Evergreen Ave, Pittsburgh, PA 15209 in Allegheny County. The practice phone is (412) 822-7410.

Dr. Karamanlakis' primary practice is Pk Medical in Pittsburgh, Pennsylvania. Dr. Karamanlakis is also affiliated with North Shore University Hospital. The medical group on file is Northwell Health Physician Partners Cardiology at Great Neck. Dmand AI also links Dr. Karamanlakis to 5 more hospitals, 4 medical groups and 1 physician office, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Karamanlakis practices, 7 sites in all. Vendor and product names are available with a free account.

Internal medicine is Dr. Karamanlakis' primary specialty in the NPI Registry, under taxonomy code 207R00000X. Dr. Karamanlakis is licensed in New York.

CMS data shows 721 Medicare services from Dr. Karamanlakis across 7 procedure codes in 2024, for 385 Medicare patients. Medicare paid $64,742 for them.

CMS counts 385 Medicare patients who saw Dr. Karamanlakis in 2024. The largest group is 75 to 84, with 150 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 23% are also on Medicaid. Their average risk score is 2.15, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Karamanlakis' median patient age at 76, with 55% women.

In 2024, Dr. Karamanlakis wrote 818 Medicare Part D claims for 110 patients. 89% of them were for generic drugs. CMS names the drug for 423 of them, across 23 drugs with 11 or more claims each, at $45,227 in total drug cost. In 2023, CMS named 478 claims across 28 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 93 out of 100 for Dr. Karamanlakis for performance year 2024, reported through an alternative payment model (APM). Dr. Karamanlakis accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

CMS Open Payments shows 4 general payments to Dr. Karamanlakis from 3 drug and device companies from 2024 to 2025. Food and beverage make up the largest share, 100% of the total. Merck Sharp & Dohme Corporation paid the most, $41.